通过mTORC1-介导的脂肪酸代谢促进质瘤的生长
在PubMed上查看摘要
概括
此摘要是机器生成的。通过激活mTORC1介导的脂肪酸代谢来促进瘤生长. 抑制ORMDL2可以抑制质瘤的进展,提高存活率.
科学领域
- 癌症学
- 分子生物学
- 生物化学
背景情况
- 脂肪酸代谢对于质瘤的发生至关重要.
- 需要研究ORMDL脂生物合成调节剂2 (ORMDL2) 在质瘤脂肪酸代谢中的作用.
研究的目的
- 研究ORMDL2在质瘤细胞脂肪酸代谢中的作用.
- 确定ORMDL2表达与质瘤患者的存活率之间的关联.
主要方法
- 对癌症基因组图谱 (TCGA) 数据和卡普兰-梅尔生存曲线的分析.
- 使用人类质瘤细胞和小鼠质瘤模型的体外研究.
- 通过CCK-8,流细胞测量,BODIPY染色,西部抹杀和qRT-PCR评估细胞增殖,细胞亡和脂肪酸代谢.
主要成果
- 在质瘤组织中ORMDL2上调,与生存率差相关.
- 抑制ORMDL2抑制了质瘤细胞的增殖,促进了细胞亡,并减少了脂质滴的形成.
- 在ORMDL2沉默的小鼠中抑制了瘤生长.
- 抑制ORMDL2降低了脂肪酸代谢因子 (FASN,ACC1,SCD1) 和mTORC1/S6K的酸化.
结论
- 在质瘤中ORMDL2过度表达,并促进瘤的进展.
- 在质瘤细胞中,ORMDL2激活了mTORC1介导的脂肪酸代谢.
- 针对ORMDL2可能是质瘤的治疗策略.
相关概念视频
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

